Coldstream Capital Management Inc Nektar Therapeutics Transaction History

Coldstream Capital Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $188 - $926	-294 Reduced 2.03%	14,161 $9,000
Q4 2022 Jan 10, 2023	BUY	$2.03 - $4.28 $29,343 - $61,867	14,455 New	14,455 $0
Q4 2018 Feb 26, 2019	SELL	$30.43 - $56.65 $206,863 - $385,106	-6,798 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $929 - $1,369	-20 Reduced 0.29%	6,798 $414,000
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $14,337 - $32,379	-310 Reduced 4.35%	6,818 $333,000
Q1 2018 May 16, 2018	BUY	$57.4 - $108.44 $13,202 - $24,941	230 Added 3.33%	7,128 $757,000
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $158,791 - $417,329	6,898	6,898 $412,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Coldstream Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Coldstream Capital Management Inc with notifications on news.